Steward Partners Investment Advisory’s BridgeBio Pharma BBIO Stock Holding History

Steward Partners Investment Advisory’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36.7K	Buy	493 +265	+116%	+$18.6K	﹤0.01%	3120
2026 Q1	$16.9K	Hold	228	–	–	﹤0.01%	3307
2025 Q4	$17.4K	Buy	228 +13	+6%	+$853	﹤0.01%	3192
2025 Q3	$11.2K	Sell	215 -1,035	-83%	-$50.5K	﹤0.01%	3355
2025 Q2	$54K	Buy	1,250 +228	+22%	+$8.29K	﹤0.01%	2435
2025 Q1	$35.3K	Hold	1,022	–	–	﹤0.01%	2550
2024 Q4	$28K	Buy	1,022 +472	+86%	+$12.2K	﹤0.01%	2620
2024 Q3	$14K	Buy	550 +350	+175%	+$9.19K	﹤0.01%	2813
2024 Q2	$5.07K	Buy	+200	New	+$5.47K	﹤0.01%	3036
2021 Q1	–	Sell	-500	Closed	-$36K	–	3416
2020 Q4	$36K	Hold	500	–	–	﹤0.01%	1821
2020 Q3	$19K	Hold	500	–	–	﹤0.01%	1907
2020 Q2	$16K	Hold	500	–	–	﹤0.01%	1848
2020 Q1	$14K	Buy	+500	New	+$15.5K	﹤0.01%	1725

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Steward Partners Investment Advisory's BBIO Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its BridgeBio Pharma (BBIO) stake by 116% in Q2 2026, buying an estimated $18.6K and bringing the position to 493 shares worth $36.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

Steward Partners Investment Advisory first reported a position in BBIO in Q1 2020 and has held it in 13 quarters since. The position peaked at $54K in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Steward Partners Investment Advisory held 493 shares of BridgeBio Pharma worth $36.7K as of Q2 2026.
Steward Partners Investment Advisory bought 265 BridgeBio Pharma shares in Q2 2026, an estimated $18.6K.
BridgeBio Pharma made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3120 holding.
Steward Partners Investment Advisory first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 13 quarters since.
Steward Partners Investment Advisory's BridgeBio Pharma position peaked at $54K in Q2 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.